Countervail Corporation


Master License Agreement Signed with University of Maryland Baltimore for the use of galantamine as a treatment for organophosphate poisoning

As its first acquisition, Countervail completes the negotiation and execution of a Master License Agreement with the University of Maryland, Baltimore for the exclusive commercialization rights to the galantamine technology as a treatment against poisoning from organphosphate (OP) compounds. OP poisons include military nerve agents such as sarin and a large class of pesticides that include chlorpyrifos and malathion.